scholarly journals Multiple complications of IVIG therapy in a patient with Guillain-Barré syndrome

2001 ◽  
Vol 67 (1) ◽  
pp. 59-59 ◽  
Author(s):  
Beth Steinberger ◽  
Teresa A. Coleman
Keyword(s):  
Ivig Therapy ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Guillain-Barré Syndrome Heralding the Diagnosis of Hodgkin Lymphoma: A Case Report

2020 ◽  
Vol 12 (3) ◽  
pp. 365-372
Author(s):  
Alawi Aqel Al-Attas ◽  
Abdulrahman Yousef Aldayel ◽  
Sara Abdullah Al Najjar ◽  
Saleh Mansoor Alkhonezan
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Ivig Therapy ◽  
Hodgkin's Lymphoma ◽  
Guillain Barre Syndrome ◽  
Ivig Treatment ◽  
Dramatic Improvement ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Tomography Scan ◽  
Fluid Test

Lymphoma is a prevalent type of lymphoid tissue malignancy that is seldom associated with Guillain-Barré syndrome (GBS). In the majority of instances, both Hodgkin’s and non-Hodgkin’s lymphoma are not proceeded by GBS. Here, we report on a case of a young patient with a manifestation and investigation suggestive of GBS, signaling an unconfirmed diagnosis of Hodgkin’s lymphoma. A cerebrospinal fluid test revealed an albuminocytological dissociation with a noteworthy rise in protein (2.32 g/L). The patient was initiated on intravenous immunoglobulin (IVIG) treatment and then showed dramatic improvement after the third dose of IVIG. His constitutional presentation alongside high inflammatory labs prompted further investigation. An enhanced pan-computed tomography scan showed multiple enlarged mediastinal and hilar lymph nodes that were confirmed as Hodgkin’s lymphoma after biopsy. Brentuximab was initiated immediately after IVIG therapy. This case highlights consideration of Hodgkin’s lymphoma as a differential diagnosis under the auspices of GBS.

scholarly journals Updates in the management of Guillain Barre Syndrome

2019 ◽  
pp. S54-S57
Author(s):  
Novi Chandra Imelda ◽  
Fadil Baktir ◽  
Fidiana . ◽  
Hanik Badriyah Hidayati ◽  
Mudjiani Basuki
Keyword(s):  
Intensive Care ◽  
Ivig Therapy ◽  
Good Prognosis ◽  
Clinical Syndrome ◽  
Guillain Barre Syndrome ◽  
Related Factors ◽  
Immunological Mechanism ◽  
Hospital Units ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Barré and Strohl in 1916. Although GBS has a good prognosis (5% mortality rate), about 10% of patients experience serious disability one year after the start of neurological onset. Recent research of GBS shows that the process involves a number of subtypes with different immunological mechanism and a spectrum of clinical syndrome of acute inflammatory neuropathy. Antibodies against peripheral nerve gangliosides and their own complements are recognized as an important mechanism of nerve damage in GBS. Pharmacokinetics of intravenous immunoglobulin (IVIg) therapy and other related factors that influence prognosis has been researched. In order to investigate the possible role of complement inhibition in GBS management, new studies will be conducted. The management of GBS should be provided in appropriate hospital units, with specialist teams, intensive care and rehabilitation facilities as essential parts. This article aims to provide updated management of GBS.Citation: Imelda NC, Baktir F, Fidiana, Hidayati HB, Basuki M. Updates in the management of Guillain Barre Syndrome. Anaesth Pain & Intensive Care 2018;22 Suppl 1:S54-S57

The effects of IVIg therapy on serum levels of neuropeptide Y and cytokines in Guillain-Barré syndrome

2019 ◽  
Vol 41 (2) ◽  
pp. 295-303 ◽  
Author(s):  
Chunrong Li ◽  
Tianfei Luo ◽  
Yanwei Cheng ◽  
Shan Liu ◽  
Lifan Qiao ◽  
...  
Keyword(s):  
Neuropeptide Y ◽  
Ivig Therapy ◽  
Serum Levels ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Cerebrospinal fluid proteome profile in patients with Guillain-Barre syndrome

2006 ◽  
Vol 33 (S 1) ◽  
Author(s):  
V. Lehmensiek ◽  
S.D. Süßmuth ◽  
G. Tauscher ◽  
S. Felk ◽  
F. Gillardon ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Proteome Profile ◽  
Guillain Barré
Sign in / Sign up

Export Citation Format

Share Document